Nektar TherapeuticsNKTR
Market Cap: $239M
About: Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Employees: 137
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
64% more capital invested
Capital invested by funds: $106M [Q1] → $173M (+$67.4M) [Q2]
50% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 24
14.21% more ownership
Funds ownership: 61.59% [Q1] → 75.8% (+14.21%) [Q2]
10% more funds holding
Funds holding: 121 [Q1] → 133 (+12) [Q2]
6% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 35
35% less call options, than puts
Call options by funds: $50K | Put options by funds: $77K
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for NKTR.